SEPTIN9 and cancer: Our results mirror the results of previous studies, which have shown lower plasma SEPT9 methylation in earlier cancer stages compared to more advanced lesions.32–34 Above all, its ability to identify patients with a positive nodal status or distant metastases stresses the potential of SEPT9 methylation as a biomarker adding valuable information to the TNM classification.